OTCMKTS:PXXLF - Poxel Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.40 -0.01 (-0.12 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$8.40
Today's Range$8.40 - $8.40
52-Week Range$8.41 - $8.64
Volume100 shs
Average Volume65 shs
Market Capitalization$206.54 million
P/E RatioN/A
Dividend YieldN/A
Poxel logoPoxel SA, a biopharmaceutical company, develops drugs for metabolic diseases with a primary focus on type II diabetes. The company's lead product pipeline includes Imeglimin, oral anti-diabetic agent that is in Phase IIb clinical trials. It is also developing PXL770, a direct AMPK activator, which is in Phase I development. The company was founded in 2009 and is headquartered in Lyon, France.

Receive PXXLF News and Ratings via Email

Sign-up to receive the latest news and ratings for PXXLF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares24,560,000
Market Cap$206.54

Poxel (OTCMKTS:PXXLF) Frequently Asked Questions

What is Poxel's stock symbol?

Poxel trades on the OTCMKTS under the ticker symbol "PXXLF."

What is the consensus analysts' recommendation for Poxel?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Poxel in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Poxel's key competitors?

Who are Poxel's key executives?

Poxel's management team includes the folowing people:
  • Mr. Thomas Kuhn, Co-Founder, CEO & Director
  • Mr. Sébastien Bolze Pharm D Ph.D., Co-Founder & Exec. VP of Non Clinical Devel.
  • Ms. Pascale Fouqueray-Grellier M.D., Ph.D., Co-Founder and Medical Director
  • Ms. Sophie Hallakou-Bozec, Co-Founder, EVP-Clinical Dev & Regulatory Affairs, SVP-R&D Pharmacology & Diabetes Research Director
  • Mrs. Pascale Malgouyres Pharm D Msc, Co-Founder, Exec. VP of Commercial Devel. & Corp. Communication and Bus. Director

Has Poxel been receiving favorable news coverage?

News coverage about PXXLF stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Poxel earned a coverage optimism score of 0.04 on Accern's scale. They also gave news stories about the company an impact score of 46.93 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Poxel?

Shares of PXXLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Poxel's stock price today?

One share of PXXLF stock can currently be purchased for approximately $8.40.

How big of a company is Poxel?

Poxel has a market capitalization of $206.54 million.

MarketBeat Community Rating for Poxel (OTCMKTS PXXLF)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  52
MarketBeat's community ratings are surveys of what our community members think about Poxel and other stocks. Vote "Outperform" if you believe PXXLF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PXXLF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.